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Objectives Continuous low-dose infusion of human atrial natriuretic peptide (hANP) in patients undergoing cardiac surgery
on cardiopulmonary bypass (CPB) inhibits the renin-angiotensin-aldosterone system and compensates for the
adverse effects of CPB.
Background We examined the influence of hANP infusion on cardiac and renal function in patients with left ventricular dys-
function undergoing coronary artery bypass grafting (CABG).
Methods The subjects were 133 patients who underwent CABG and had a pre-operative ejection fraction 35%. They were
randomized to receive 0.02 g/kg/min of hANP from the initiation of CPB (hANP group) or placebo (saline) infusion.
Results Early post-operative mortality did not show a significant difference between the 2 groups, but perioperative com-
plications were significantly less frequent in the hANP group (p  0.015). Long-term all-cause mortality showed
no difference, but the cardiac death-free rate at 5 or 8 years post-operatively was 98.5% in the hANP group and
85.5% in the placebo group (p  0.0285). Post-operative ejection fraction was significantly larger and the post-
operative brain natriuretic peptide level was significantly lower in the hANP group. Serum creatinine was signifi-
cantly lower in the hANP group than the placebo group at 1 month, 6 months, and 1 year post-operatively,
whereas the estimated glomerular filtration rate was significantly higher in the hANP group at these times.
Conclusions In patients with left ventricular dysfunction undergoing CABG, hANP showed renal- and cardio-protective effects
and reduced post-operative complications. It also improved the long-term prognosis. We suggest that hANP
should be considered as part of perioperative management of patients with cardiac dysfunction undergoing car-
diac surgery. (NU-HIT trial for LVD; UMIN000001652) (J Am Coll Cardiol 2010;55:1844–51) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.085t
(
(
o
m
phe results of coronary artery bypass grafting (CABG) have
mproved in recent years due to advances in operative
echniques and post-operative management, but the opera-
rom the Departments of *Cardiovascular Surgery and †Cardiology, Nihon Univer-
ity School of Medicine, Tokyo, Japan. This study was conducted with support of a
esearch Grant from the Japanese Ministry of Education, Culture, Sports, Science
nd Technology (No.21591805); a Nihon University Medical School Alumni 60th
nniversary Medical Research Grant; and a Nihon University Medical School
oundation 50th Anniversary Medical Research Grant.r
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ccepted November 2, 2009.ive mortality of patients with left ventricular dysfunction
LVD) undergoing CABG is still high at 4.4% to 11.6%
1–4). These patients also tend to require prolonged post-
perative hospital stay for heart failure or serious arrhyth-
See page 1852
ias, and the long-term prognosis is still unsatisfactory. In
atients with LVD undergoing CABG, Nardi et al. (5)
eported a cardiac death rate of 20.4% and a cardiac
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April 27, 2010:1844–51 Low-Dose hANP During CABGeath-free rate of 63% at 10 years post-operatively. Appoo
t al. (1) classified patients into 3 groups according to their
re-operative left ventricular ejection fraction (LVEF) (i.e.,
ow EF [EF 30%], medium EF [EF 30% to 50%], and
ormal EF [EF 50%] groups) and reported that the
-year survival rate was significantly lower in the low EF
77.7%) and medium EF groups (85.5%) than in the normal
F group (91.2%). Therefore, careful interdisciplinary care
uring the perioperative period is required in these patients.
Human atrial natriuretic peptide (hANP) is a hormone
hat is secreted in response to expansion of the atrial wall.
ANP has a vasodilator action, a potent natriuretic effect,
nhibits the renin-angiotensin-aldosterone system (RAAS),
nd dilates the coronary arteries (6,7). It is used clinically in
apan to treat heart failure. Heart surgery with cardiopulmo-
ary bypass (CPB) leads to an increase of circulating hormones
rom the RAAS and catecholamines as well as decreased urine
utput and accumulation of water in the third space. Admin-
stration of hANP might counter such changes, and continu-
us low-dose infusion of hANP from the start of CPB has
een reported to inhibit the RAAS and show a potent
atriuretic effect, thus compensating for the adverse influence
f CPB (8). In subsequent research, hANP has been shown to
nhibit left ventricular (LV) remodeling and ischemia-
eperfusion injury as well as have a myocardial protective effect
9–11). The NU-HIT (Nihon University working group study
f low-dose Human ANP Infusion Therapy during cardiac
urgery) was designed to examine the efficacy of hANP in
atients undergoing cardiac surgery. The present research
nrolled patients with LVD and a poor prognosis who were
ndergoing CABG with CPB (NU-HIT trial for LVD). This
s the first study to investigate the effects of hANP in patients
ith LVD undergoing cardiac surgery.
ethods
tudy protocol. The NU-HIT trial for LVD was a ran-
omized, double-blind, placebo-controlled study of patients
ho had LVD and underwent CABG with CPB. The
atients with cardiogenic shock and hemodialysis and hav-
ng off-pump CABG were excluded. Among patients un-
ergoing CABG at Nihon University Itabashi Hospital
rom March 1997 to March 2008, 135 were enrolled in the
U-HIT trial for LVD, and they had LVD with an LVEF
35% on pre-operative LV angiography. The EF was
easured by center-line method on LV angiography. The
atients were randomized into 2 groups, which were a
ANP group that received an infusion of hANP (Suntory,
nc., Osaka, Japan; and Daiichi-Sankyo Pharmaceutical,
nc., Tokyo, Japan) from initiation of CPB and a placebo
roup that was administered physiological saline (Fig. 1).
reatment was done in a blinded manner. Because hANP is
pproved for acute cardiac failure but not for administration
uring cardiac surgery, approval for this study was received
rom the Ethics Committee of Nihon University Itabashiospital, the details of the study were explained to subjects,nd informed consent was ob-
ained. This study was registered
ith the University Hospital
edical Information Network
UMIN000001652).
Approval was obtained for a
tarting dose of 0.1 g/kg/min for
cute cardiac failure, but the ini-
ial low dose of 0.02 g/kg/min
as selected for this study be-
ause the subjects of this study
id not have acute cardiac failure.
dministration of hANP or pla-
ebo was initiated at the start of
PB, with the dosage decreased
o 0.01 g/kg/min at the com-
encement of oral medication
nd then discontinued after 12 h.
sosorbide dinitrate was admin-
stered to all subjects from before
PB withdrawal until com-
encement of oral medication.
he CPB was performed by
onpulsatile perfusion at a low
emperature (target rectal tem-
erature: 34°). The bypass was
onnected to the left internal
horacic artery in patients under-
oing surgery on the territory of
he left anterior descending artery and a radial arterial
nd/or great saphenous venous graft for other sites. The
evels of atrial natriuretic peptide (ANP), brain natriuretic
Figure 1 Study Population
A total of 135 patients registered in the NU-HIT (Nihon University working group
study of low-dose Human ANP Infusion Therapy during cardiac surgery) of coro-
nary artery bypass grafting (CABG) for left ventricular dysfunction (LVD) were
randomly assigned to receive human atrial natriuretic peptide (hANP) therapy
(hANP group) or placebo therapy (placebo group).
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  brain natriuretic
peptide
CABG  coronary artery
bypass grafting
CPB  cardiopulmonary
bypass
CPK-MB  creatine kinase
isoenzyme-myocardial band
CRF  chronic renal failure
EF  ejection fraction
eGFR  estimated
glomerular filtration rate
hANP  human atrial
natriuretic peptide
ICU  intensive care unit
LV  left ventricular
LVD  left ventricular
dysfunction
LVEF  left ventricular
ejection fraction
RAAS  renin-angiotensin-
aldosterone system
sCr  serum creatinine
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Low-Dose hANP During CABG April 27, 2010:1844–51eptide (BNP), plasma renin activity, angiotensin II, aldo-
terone, and serum creatinine (sCr) as well as the estimated
lomerular filtration rate (eGFR) were measured pre-
peratively, on return to the intensive care unit (ICU) after
urgery and at 1 and 3 days and 1 week post-operatively.
he creatine kinase isoenzyme-myocardial band (CPK-
B), BNP, sCr, and eGFR were also assessed at 1 and 6
onths and 1 year post-operatively. The eGFR was calcu-
ated by the method proposed for Japanese persons by the
apanese Society of Nephrology (men: 194  Cr1.094 
ge0.287, women: 194  Cr1.094  age0.287  0.739)
12). The LVEF was measured pre-operatively and post-
peratively (1 week, 1 month, and 1 year) by echocardiog-
aphy, with experienced echocardiographers using Simp-
on’s method.
nd points. The primary end points were: 1) early post-
perative outcome (operative mortality and complications);
nd 2) long-term results (cardiac death- and event-free rate,
verall survival rate after surgery). Post-operative complica-
ions were categorized as central nervous system disorders,
ardiovascular disorders (low output syndrome, heart fail-
re, perioperative myocardial infarction, and refractory ar-
hythmia), respiratory failure, acute renal failure (requiring
ialysis), gastrointestinal disorders (a requirement for high
alorie alimentation such as in patients with gastrointestinal
leeding, ileus, liver dysfunction), infections (septicemia,
neumonia, mediastinitis, and so forth), and other disorders
equiring long-term ICU management. Cardiac events in
his study were defined as: cardiac failure requiring treat-
ent with cardiotonic agents or assisted circulation for 1
eek or longer after surgery, cardiac failure requiring hos-
ital treatment after discharge, perioperative myocardial
nfarction, recurrent ischemic heart disease after discharge,
rrhythmia requiring treatment due to effect on post-
perative hemodynamic status, and arrhythmia requiring
ospital treatment after discharge. The secondary end
oints were: 1) cardiac function (EF, BNP); 2) post-
perative CPK-MB (immediately after surgery; 3 h after
urgery; and on the first, second, and third days after
urgery); 3) renal function (sCr, eGFR, the maximum value
nd rate of increase of sCr [%Cr  (maximum sCr –
re-operative sCr)/pre-operative sCr 100]), an increase of
Cr by 0.3 mg/dl compared with the pre-operative value;
nd 4) ANP, renin activity, angiotensin-II, aldsterone.
tatistical analysis. Data are expressed as the mean  SD.
aseline comparisons between the groups and all other
tatistical analyses were performed with Student unpaired
test and Fisher exact test where appropriate for categorical
ata. A p value  0.05 was considered to indicate statistical
ignificance. Data with a skewed distribution (BNP, EF,
NP, RAAS, serum Cr, and eGFR) were analyzed by
epeated measures analysis of variance, and Scheffe’s test was
erformed as a post hoc test.
All-cause mortality, the cardiac death-free rate, and theardiac event-free rate were analyzed by the Kaplan-Meier
a
Rethod, and significance of differences was assessed by the
og-rank test.
esults
atient enrollment. Initially, 135 patients were enrolled in
he NU-HIT trial for LVD, but 2 of these patients were
witched to off-pump CABG during the operation and thus
ere excluded from the trial, leaving 133 patients. Among
hese 133 patients, 68 were assigned to the hANP group
nd 65 were assigned to the placebo group (Fig. 1). All
atients were followed in our institute. Completion of
ollow-up was possible in all patients.
aseline characteristics. Pre-operative patient characteris-
ics showed no significant differences between the 2 groups
Table 1).
urgical procedures and post-operative management.
able 2 shows the number of bypasses, aortic cross-
lamping time, extracorporeal circulation time, mechanical
upport, and post-operative oral medications. No significant
ifferences were observed between the hANP and placebo
roups. Routine perioperative management of the blood
ressure response was conducted. The duration of hANP
nfusion was 2.8  1.1 days in the hANP group, whereas
hysiological saline was infused for 3.4  1.8 days in the
lacebo group, and the period was significantly shorter in
linical Profile of the 2 GroupsTable 1 Clinical Profile of the 2 Groups
hANP Group
(n  68)
Placebo Group
(n  65) p Value
Age (yrs) 65.9 10.4 65.9 8.9 0.977
Sex (male/female) 57/11 57/8 0.623
Body surface area (m2) 1.67 0.17 1.65 0.18 0.570
EuroSCORE 5.8 3.9 5.6 3.6 0.643
Diagnosis
AMI 8 (11.8%) 6 (9.2%) 1.00
OMI 41 (60.3%) 40 (61.5%) 1.00
Unstable angina 17 (25.0%) 17 (26.2%) 0.779
Stable angina 2 (2.9%) 2 (3.1%) 0.859
Risk factor
Diabetes mellitus 43 (63.2%) 38 (58.5%) 0.598
Hypertension 47 (69.1%) 52 (80.0%) 0.411
Hyperlipidemia 36 (52.9%) 26 (40.0%) 0.165
Obesity 22 (32.4%) 14 (21.5%) 0.177
Smoking 34 (50.0%) 33 (50.8%) 1.00
Cerebrovascular disease 4 (5.9%) 5 (7.6%) 0.741
Chronic renal failure 4 (5.9%) 2 (3.1%) 0.681
Oral medication
ARB 19 (27.9%) 19 (29.2%) 1.00
ACE-I 12 (17.6%) 10 (15.4%) 0.817
Calcium antagonist 16 (23.5%) 20 (30.8%) 0.435
Beta-blocker 14 (20.6%) 18 (27.7%) 0.418
Aldosterone blocker 10 (14.7%) 8 (12.3%) 0.802
Statin 19 (27.9%) 17 (26.2%) 0.848
Average follow-up (yrs) 4.1 2.9 4.0 3.1 0.853
alues are mean  SD or n (%).
ACE-I  angiotensin-converting enzyme inhibitor; AMI  acute myocardial infarction; ARB 
ngiotensin receptor blocker; Ca calcium; EuroSCORE European System for Cardiac Operative
isk Evaluation; hANP  human atrial natriuretic peptide; OMI  old myocardial infarction.
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April 27, 2010:1844–51 Low-Dose hANP During CABGhe hANP group (p  0.027). Both hANP and saline were
nfused continuously, and administration was not discon-
inued for reasons such as hypotension in any of the
atients. In the ICU, significantly fewer patients from the
ANP group required intravenous administration of furo-
emide, and the dose was significantly lower. Potassium
upplementation was also required less frequently in the
ANP group (Table 2).
rimary end points. EARLY POST-OPERATIVE OUTCOME.
o significant differences were observed in the 30- and
80-day mortality rate between groups, although the inci-
ence of post-operative complications including arrhythmia
as significantly lower in the hANP group. The time in
CU and the hospital study were both significantly shorter
n the hANP group (ICU time: p  0.0393, hospital study:
 0.0434) (Table 3).
ONG-TERM RESULTS. Late post-operative death occurred
n 6 patients from the hANP group and in 5 from the
perative and Post-Operative DataTable 2 Operative and Post-Operative Data
hANP Group
(n  68)
Placebo Group
(n  65) p Value
ACCT (min) 28.1 12.0 28.0 13.7 0.963
CPBT (min) 97.0 21.7 96.8 24.0 0.945
Emergency 15 (22.1%) 14 (21.5%) 1.00
Bypass 3.1 0.8 3.1 0.9 0.823
Arterial graft use 61 (89.7%) 58 (89.2%) 1.00
IABP support 1 3 0.358
Venoarterial bypass support 0 2 0.237
Inotropic support
Dopamine 33 (48.5%) 30 (46.2%) 0.863
Dobutamine 20 (29.4%) 17 (26.2%) 0.847
Norepinephrine 2 (2.9%) 4 (6.2%) 0.434
PDE-III inhibitor 21 (30.9%) 21 (32.3%) 1.00
Furosemide 14 (20.6%) 28 (43.1%) 0.009
Dosage of furosemide (mg) 11.7 24.3 31.5 42.8 0.0014
Dosage of potassium (mEq) 104.0 66.1 211.7 140.2 0.0001
Maximum sCr (mg/dl) 1.14 0.41 1.29 0.92 0.0001
Increase of Cr (%) 4.1 40.7 47.4 61.8 0.0001
(Preop – Max sCr) 0.3 mg/dl 7 (10.3%) 26 (40.0%) 0.0001
CPK-MB (U/l)
Immediately after surgery 41.237.7 49.1 37.3 0.226
3 h after surgery 41.2 51.9 49.5 35.0 0.285
Day 1 28.4 47.7 46.8 51.2 0.034
Day 2 13.3 15.3 22.3 25.2 0.014
Day 3 8.4 4.1 13.0 10.6 0.001
Post-operative oral medication
ARB 18 (26.5%) 22 (33.8%) 0.45
ACE-I 6 (8.8%) 3 (4.6%) 0.493
Calcium antagonist 39 (57.4%) 34 (52.3%) 0.604
Beta-blocker 17 (25.0%) 20 (30.8%) 0.562
Aldosterone blocker 27 (39.7%) 26 (40.0%) 1.00
Statin 26 (38.2%) 26 (40.0%) 0.861
alues are mean  SD, n (%), or n.
ACCT  aortic cross-clamp time; CPBT  cardiopulmonary bypass time; CPK-MB  creatine
inase isoenzyme-myocardial band; Cr  creatinine; IABP  intra aortic balloon pumping; Max 
aximum; PDE  phosphodiesterase; Preop  pre-operative; other abbreviations as in Table 1.lacebo group (Table 3). The overall survival rate (including
Voncardiac death) in the hANP group and the placebo
roup was 97.0% and 90.8% at 2 years post-operatively;
7.0% and 84.1% at 5 years post-operatively; and 87.0% and
4.1%, respectively, at 8 years post-operatively. There were
o significant differences between the 2 groups (p 0.5078)
Fig. 2). However, the cardiac death-free rate in the hANP
roup and the placebo group was 98.5% and 92.3% at 2
ears post-operatively, 98.5% and 85.5% at 5 years post-
peratively, and 98.5% and 85.5%, respectively, at 8 years
ost-operatively. These rates were significantly higher in
he hANP group than in the placebo group (p  0.0285)
Fig. 2). Cardiac events occurred in 15 patients from the
ANP group and in 38 from the placebo group (Table 3). The
ardiac event-free rate in the hANP group and the placebo
roup was 82.1% and 49.0% at 2 years post-operatively,
2.1% and 41.5% at 5 years post-operatively, and 72.7% and
ost-Operative DataTable 3 Post-Operative Data
hANP Group Placebo Group p Value
Early post-operative outcome
n 68 65
30-day death 0 (0%) 2 (3.1%) 0.237
Cause of death
Heart failure 0 1
Hepatic insufficiency 0 1
180-day death 0 (0%) 3 (4.6%) 0.114
Cause of death
Heart failure 0 2
Hepatic insufficiency 0 2
Complications 4 (5.9%) 10 (15.4%) 0.015
Heart failure 1 5
Cerebral infarction 1 1
Hemorrhage 1 0
Mediastinitis 1 1
Hepatic insufficiency 0 1
Acute renal failure 0 1
Pneumonia 0 1
Post-operative arrhythmias 14 33 0.0003
Ventricular arrhythmia 2 10 0.0151
Atrial fibrillation 12 23 0.0296
ICU stay (days) 3.6 1.9 4.4 2.6 0.0393
Hospital stay (days) 13.7 7.6 19.3 21.0 0.0434
Long-term results
n 68 62
Late post-operative death 6 (8.8%) 5 (8.1%) 1.0
Cause of death
Acute myocardial infarction 1 0
Heart failure 0 3
Arrhythmia 0 1
Cerebrovascular disease 3 0
Septicemia 1 0
Malignancy 1 1
Cardiac events 15 (22.1%) 38 (61.3%) 0.0001
Heart failure 2 12
Arrhythmia 11 25
Ischemic heart disease 2 1alues are n, n (%), or mean  SD.
hANP  human atrial natriuretic peptide; ICU  intensive care unit.
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Low-Dose hANP During CABG April 27, 2010:1844–518.1%, respectively, at 8 years post-operatively. These rates
ere significantly higher in the hANP group than in the
lacebo group (p  0.0001) (Fig. 2).
econdary end points. CARDIAC FUNCTION. The LVEF
as significantly larger in the hANP group than in the
lacebo group at 2 weeks, 1 month, 6 months, and 1 year
ost-operatively. The BNP level was significantly lower in
he hANP group than in the placebo group from Day 1
ntil 1 year post-operatively. Compared with the pre-
perative value, the level in the hANP group was signifi-
antly lower from 1 month after surgery. In the placebo
roup, the levels on days 1 and 3 post-operatively were
ignificantly higher than the pre-operative value. Although
NP decreased thereafter, it did not show a significant
ecline compared with the pre-operative value throughout
he entire post-operative course (Table 4). No significant
ifferences were observed in immediate post-operative
PK-MB levels between groups, although CPK-MB levels
ere significantly lower in the hANP group than the
lacebo group from day 1 post-operatively (Table 2).
ENAL FUNCTION. The pre-operative sCr was higher in the
ANP group than the placebo group, because there were 4
atients with chronic renal failure (CRF) in the former
roup, although the difference was not significant (p 
.1454). At 1 month, 6 months, and 1 year post-operatively,
Cr was significantly lower in the hANP group than the
lacebo group. When CRF patients were excluded from
oth groups, the hANP group showed a significantly lower
Cr than the placebo group throughout the entire post-
perative course (from return to ICU until 1 year post-
peratively) (Fig. 3). The pre-operative eGFR was lower in
he hANP group than the placebo group, although the
ifference was not significant (p  0.051). At 1 month, 6
onths, and 1 year post-operatively, the hANP group had
significantly higher eGFR than the placebo group. When
RF patients were excluded from both groups, the hANP
roup had a significantly higher eGFR than the placebo
roup throughout the entire post-operative course (from
eturn to ICU until 1 year post-operatively) (Fig. 4). The
RF patients had a pre-operative sCr 1.5 mg/dl and were
ot receiving dialysis. The peak sCr and the rate of Cr
ncrease until 1 month post-operatively were significantly
ower in the hANP group, and the number of subjects with a
.3-mg/dl or higher increase in sCr over the pre-operative
alue was significantly smaller in the hANP group (Table 2).
nly 1 patient from the hANP group required dialysis over the
ong term. In the placebo group, 2 patients started dialysis
ithin 2 years post-operatively, and 1 each did so after 3 and 5
ears, for a total of 4 patients (p  0.054). One of these 4
atients had CRF pre-operatively, but the other 3 patients had
ormal sCr values pre-operatively.
NP and RAAS. In the hANP group, the ANP level
ncreased rapidly to approximately 10 times the pre-
perative value. Renin was significantly higher in theyears
p<0.0001
Cardiac event-free rate
Overall survival rateA
C
Cardiac death-free rate B
%
p=0.5078 
0 1 2 3 5 7 10
hANP 68 67 46 39 18 10 6
placebo 65 59 40 35 21 13 4
%
%
p=0.0285
years
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Figure 2 Overall Survival Rate, Cardiac
Death-Free Rate, and Cardiac Event-Free Rate
(A) The overall survival rate showed no significant difference between the 2
groups. (B) The cardiac death-free rate was significantly higher in the human
atrial natriuretic peptide (hANP) group than in the placebo group. (C) The car-
diac event-free rate was significantly higher in the hANP group than in the pla-
cebo group. Solid lines  hANP group; dashed lines  placebo group.ANP group on return to the ICU but tended to be lower
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April 27, 2010:1844–51 Low-Dose hANP During CABGfter that, although the difference was not significant.
ngiotensin-II was significantly lower in the hANP group
n return to the ICU and at 1 day and 1 week post-
peratively. Aldosterone was significantly lower in the
ANP group on return to the ICU and at 1 week post-
peratively (Table 4).
iscussion
his study showed that administration of hANP to CABG
atients with poor cardiac function was effective for improv-
ng both renal and cardiac function in the early post-
perative period and also over the long term. Even though
ANP was only administered for a few days in the acute
tage, a potent cardio- and renal-protective effect was
emonstrated. The preventive effect of hANP on ischemic
ecirculatory disorder, which we reported in our previous
tudy, was also demonstrated by the results of post-operative
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Figure 3 sCr Profile
(A) Serum creatinine (sCr) was significantly lower in the human atrial natri-
uretic peptide (hANP) group than in the placebo group. (B) This difference was
more marked after patients with chronic renal failure (CRF) were excluded.
Solid circles  hANP; open circles  placebo. *p  0.05 for hANP versus pla-
cebo; **p  0.01 for hANP versus placebo.CPK-MB in this study. During the early post-operativeBN T
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Low-Dose hANP During CABG April 27, 2010:1844–51eriod, BNP was significantly increased in the placebo
roup but not in the hANP group. The cardio-protective
ffect of hANP was also evident in BNP values over the long
erm, and the rates of cardiac death and cardiac events were
educed. The renal-protective effect of hANP was clear
rom the sCr and eGFR data in the acute post-operative
eriod and also over the long term. Angiotensin-II and
ldosterone levels at 1 week post-operatively were, upon
xamination of the RAAS, significantly lower in the hANP
roup. In addition, they recovered to the pre-operative levels
n the hANP group but did not recover in the placebo group
ven 1 week post-operatively. These results showed that
ANP exerted an early effect countering the adverse influ-
nces of extracorporeal circulation. This study is the first
nvestigation of CABG patients with LVD that has assessed
ardiac function over the long term post-operatively. We
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Figure 4 Profile of eGFR
(A) Estimated glomerular filtration rate (eGFR) was significantly lower in the
hANP group than in the placebo group. (B) The difference was more marked
after patients with CRF were excluded from analysis. Solid circles  hANP;
open circles  placebo. *p  0.05 for hANP versus placebo; **p  0.01 for
hANP versus placebo. Abbreviations as in Figure 3.uggest, because of the results of this study, that hANP bhould be considered as part of perioperative management
or protection of cardiac and renal function.
Both hANP (carperitide) and BNP (nesiritide) are al-
eady used to treat heart failure and have recently been
eported to be effective for acute myocardial infarction. A
arge-scale multicenter study (J-WIND [Japan-Working
roups of Acute Myocardial Infarction for the Reduction of
ecrotic Damage by ANP or Nicorandil] study) on admin-
stration of hANP after reperfusion therapy for acute
yocardial infarction showed that the infarct size was
ignificantly reduced, cardiac function was improved, and
ardiac death and heart failure rates were significantly lower
n the hANP group than in the placebo group (13). In
ddition, Kasama et al. (14) reported that administration of
ANP for 48 h after percutaneous coronary intervention in
atients with acute myocardial infarction improves cardiac
ympathetic activity and prevents LV remodeling.
Small-scale studies of hANP in heart surgery have already
een reported, but there have been few randomized con-
rolled trials. Valsson et al. (15) administered hANP for 30
in post-operatively to patients who had acute renal failure
ssociated with heart failure and reported a 62% increase of
rine volume, 43% increase of GFR, and 38% increase of
enal blood flow, along with a 30% decrease of renal vascular
esistance. The same group also reported a larger study that
howed less need for dialysis and a higher dialysis-free
urvival rate (16). Hayashida et al. (17) studied patients
ndergoing mitral valve surgery with extracorporeal circu-
ation and reported that their hANP group had a signifi-
antly higher urine output as well as better hemodynamic
tatus and fluid balance. Human atrial natriuretic peptide
as a diuretic effect, due to a direct action on the glomeruli
nd renal tubules. It prevents worsening of the electrolyte
alance after high-dose administration of diuretics, in-
reases urinary sodium excretion, and prevents renal paren-
hymal damage (18). From our results and those of Valsson
t al. (15), Swärd et al. (16), and Hayashida et al. (17), it is
lear that hANP both inhibits the RAAS and stimulates renal
unction.
Human atrial natriuretic peptide is only used in Japan at
resent, whereas BNP has not been approved in Japan but
s used in Western countries. The NAPA (Nesiritide
dministered Peri-Anesthesia) trial on use of BNP during
eart surgery was performed in the U.S. (19), with subjects
imilar to those of the present study. In the BNP group, the
eak sCr was lower and GFR was higher, whereas the
urvival rate at 180 days post-operatively was significantly
igher in the BNP group than the placebo group (19). Our
tudy of hANP obtained results comparable to those of the
APA trial.
In the NAPA trial, early post-operative (until discharge)
enal function and mortality until 180 days after surgery
ere investigated, whereas in our trial we evaluated not only
arly post-operative but also until 1 year post-operative renal
nd cardiac function and examined the RAAS, which has
een reported to be affected more by hANP. Moreover, the
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April 27, 2010:1844–51 Low-Dose hANP During CABGean observation period of this study was as long as 4 years.
his study yielded the interesting finding that several days
f post-operative administration can affect the long-term
rognosis.
We showed that hANP improve both renal and cardiac
unction in the acute post-operative period as well as over
he long term. A trial of BNP in patients with pre-operative
enal dysfunction (eGFR 60 ml/min) was reported by the
ayo Clinic (20), showing better post-operative results in
he BNP group.
Few reports have been published about the use of hANP
nd BNP in heart surgery, and there have been no compar-
sons of these 2 peptides. From the results of our study, the
APA trial, and the Mayo Clinic study, it seems that use of
ANP or BNP during heart surgery can improve post-
perative renal function and cardiac function in patients
ith renal or cardiac dysfunction, that the incidence of
ost-operative complications is reduced, and that long-term
mprovement is also obtained.
Accordingly, we suggest that perioperative use of hANP
r BNP should be considered in patients with cardiac
ysfunction undergoing cardiac surgery.
tudy limitations. In this study, we demonstrated the
fficacy of hANP in patients with cardiac dysfunction
ndergoing CABG, and we suggest that hANP treatment
e considered as a new method of perioperative manage-
ent. However, there are limitations to the conclusions that
an be drawn from this study, because of the low subject
umbers, with only 133 cases. A large-scale future study
hould verify our results and clarify the efficacy of hANP
herapy and associated problems.
onclusions
n patients with LV dysfunction undergoing CABG, hANP
howed renal- and cardio-protective effects and reduced
ost-operative complications. It also improved the long-
erm prognosis. We suggest that hANP should be consid-
red as part of perioperative management of patients with
ardiac dysfunction undergoing cardiac surgery.
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